Tags : Nicolas Mosimann

Deal & transactions

Kellerhals Carrard advises Biognosys on its partnership with Bruker

Biognosys and Bruker Corporation announced a strategic partnership, in which Bruker has made a majority-ownership investment in the company. Several of Biognosys’ earlier investors have sold their shares to Bruker in a secondary transaction, and Bruker will make new primary investments in Biognosys. Biognosys mass spectrometry-based proteomics solutions help CRO services and proteomics software customers […]

Deal & transactions

MoonLake Immunotherapeutics closes combination with Helix Acquisition

Kellerhals Carrard acted as Swiss legal advisor to MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company elevating care with innovative immunology therapeutics, in the closing of its previously announced business combination with Helix Acquisition Corp. (“Helix”), a publicly traded special purpose acquisition company.   The business combination was unanimously approved by Helix’s board of directors and was approved […]

Deal & transactions

Katadyn Group acquired by a group of entre­pren­eurs led by Kontivia

Katadyn Group, a Swiss-based spe­cial­ist in port­able water fil­ters and trekking food, has been acquired by a group of entre­pren­eurs led by Kontivia, a long-term, down-to-earth investment company and invests together with selected entrepreneurial families in established medium- sized companies in Switzerland and southern Germany. The acquisition was consummated through Bifolia Holding which was renamed in Katadyn Group following the closing of the transaction.  The majority shareholder of Katadyn Holding, Adrian Schmassmann, and […]

Deal & transactions

Helix Acquisition Corp business agreement with MoonLake. The advisors

Helix Acquisition Corp, a Nasdaq-listed special purpose acquisition company and MoonLake Immunotherapeutics, a Swiss based clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases agreed on a business combination. At closing of the envisaged business combination, MoonLake will have access to approximately USD 230 million in cash (subject to redemptions), […]

Banking & Finance

MoonLake Immunotherapeutics closes Series A Funding Round – The Advisors

MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseaseshas closed a Series A financing round, lead by BVF Partners LP. Other investors included Merck KGaA, Darmstadt, Germany. MoonLake Immunotherapeutics was established by an international team of immunology specialists to create next-level therapies for inflammatory skin and joint […]


Kellerhals Carrard advises Moderna Switzerland on Covid-19 vaccination

Kellerhals Carrard, under the responsibility of partners Claudia Götz Staehelin (pictured), Oliver M. Brupbacher and Nicolas Mosimann, advised Moderna on legal and regulatory aspects related to the establishment of its supply chain for its COVID-19 Vaccine and Swiss launch preparations, including trade compliance and regulatory aspects.